The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2010Investigation of PDE10a Inhibitors for Parkinsons Disease.PI is Bart Ellenbroek
Objective/Rationale:
Phosphodiesterase 10A (PDE10A) is an intracellular protein that is located almost exclusively within the basal ganglia. It plays an important role in information transfer within... -
Therapeutics Development Initiative, 2010Targeting alpha-synuclein-lipid interactions in preclinical Parkinson's disease models
Objective/Rationale:
Parkinson’s disease is caused by loss of dopaminergic neurons in significant part secondary to accumulation/aggregation of a protein called a-synuclein. New information has shown... -
Therapeutics Development Initiative, 2010Assessment of the Neurorestorative Potential of Enhanced Neurotrophic Support via Positive Glutamatergic Modulation in the MPTP Pre-clinical Model of PD
Objective/Rationale:
Parkinson’s is a neurodegenerative disease of the part of the brain that controls motor function. Brain-derived neurotrophic factors promote survival of dopaminergic neurons... -
Therapeutics Development Initiative, 2010Optimization of Selective Mu Opioid Receptor Antagonists for the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
Promising Outcomes of Original Grant:
The major objectives of the original grant were to improve upon the μ receptor (MOR) selectivity of ADC5510 and to find compounds that had superior pharmacokinetic... -
Therapeutics Development Initiative, 2010Metal Complexation with Levodopa to Improve Continuous Dopaminergic Stimulation
Objective/Rationale:
Our goal is to market a new levodopa/carbidopa orally-administered drug product with pharmacokinetics (PK) similar to that seen with direct infusion products. Currently, orally... -
Therapeutics Development Initiative, 2010Novel, Selective and Potent Brain-penetrant Small Molecule Inhibitors of Cytosolic Hsp90
Objective/Rationale:
Our objective is to develop novel drug candidates as therapeutics for Parkinson's disease by selectively targeting and inhibiting the heat shock protein-90 (Hsp90) in the brain...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.